GHRS Projected Dividend Yield
Ord/GH Research PLC ( NASDAQ : GHRS )GH Research is a holding company. Through its subsidiary, Co. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. Co.'s initial focus is on developing its novel and proprietary 5-Methoxy-N,N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Co.'s portfolio includes GH001, Co.'s proprietary inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, Co.'s proprietary injectable 5-MeO-DMT product candidate. 20 YEAR PERFORMANCE RESULTS |
GHRS Dividend History Detail GHRS Dividend News GHRS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |